Drug intelligence / Profile preview

bupivacaine + magnesium sulfate

Development stage: Approved
Modality: Small Molecules
Administration: Intraarticular, Epidural, Peripheral Nerve Block, Wound Infiltration, Intrathecal

Overview

A combination of bupivacaine, an amide local anesthetic, and magnesium sulfate, an NMDA receptor antagonist. This combination is used in various anesthetic procedures including intraarticular injections, epidural anesthesia, peripheral nerve blocks, and wound infiltration. Magnesium sulfate acts as an adjuvant to bupivacaine, enhancing and prolonging its analgesic effects while reducing the need for postoperative analgesics.

Other names: magnesium sulphate + bupivacaine

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)NaV (Voltage-gated sodium channels)Kir (Inward-rectifier potassium channels)

Beyond the preview

Go deeper on bupivacaine + magnesium sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + magnesium sulfate.

Explore the full profile